We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate
Read MoreHide Full Article
GSK plc (GSK - Free Report) announced that it is in-licensing exclusive worldwide rights from China biopharmaceutical company, Hansoh Pharma, to develop and commercialize the latter’s investigational antibody-drug conjugate (ADC) candidate, HS-20093, in lung cancer and other solid tumor indications. However, Hansoh retains exclusive rights to the candidate in China’s mainland, Hong Kong, Macau, and Taiwan.
HS-20093 is a B7-H3 targeted ADC utilizing a clinically validated topoisomerase inhibitor payload. It is the second investigational ADC that GSK in-licensed from Hansoh.
It is important to note that in October 2023, GSK bought the first ADC from Hansoh, HS-20089. HS-20089 is a B7-H4 targeted ADC, currently being developed in China in mid-stage studies. Per GSK, HS-20089 has the potential to become a best-in-class treatment for ovarian and endometrial cancer with opportunities in other solid tumors.
Per the press release, HS-20093 is currently being evaluated in ongoing phase I and II studies in China. Data from the phase I ARTEMIS-001 study for HS-20093 in advanced solid tumors was recently presented at a medical conference. In the early-stage study, treatment with the candidate demonstrated initial clinical activity in small-cell lung cancer, non-small-cell lung cancer and sarcoma with multiple confirmed responses.
HS-20093 demonstrated a manageable safety profile, too, which was also encouraging.
Year to date, shares of GSK have gained 3% against the industry’s 16.9% decline.
Image Source: Zacks Investment Research
Per the terms of the agreement, GSK is liable to make an upfront payment of $185 million to Hansoh in consideration of the exclusive license to develop and commercialize HS-20093 for lung cancer and other solid tumor indications.
GSK might be further liable to pay potential milestone payments of up to $1.525 billion to Hansoh, which brings the total deal value to approximately $1.9 billion.
Additionally, GSK will make tiered royalty payments on global net sales of HS-20093 in its territories, subject to successful commercialization. The closing of the transaction is contingent upon the meeting of certain customary and regulatory conditions.
GSK has a strong portfolio of marketed drugs for oncology indications, primarily boosted by growth in Jemperli (dostarlimab) and Zejula (niraparib) sales, approved for various gynecologic cancer indications. In the first nine months of 2023, GSK’s oncology drugs together recorded revenues of £487 million, representing year-over-year growth of 9% at constant exchange rate.
In the past 30 days, the Zacks Consensus Estimate for Puma Biotech’s 2023 earnings per share (EPS) has decreased from 73 cents to 72 cents. During the same time frame, the consensus estimate for Puma Biotech’s 2024 EPS has increased from 62 cents to 64 cents. In the year so far, shares of PBYI have lost 7.6%.
PBYI’s earnings beat estimates in three of the last four quarters while missing on one occasion, delivering a four-quarter average earnings surprise of 76.55%.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2023 loss per share has remained constant at 3 cents. The consensus estimate for ADMA Biologics’ 2024 EPS is pegged at 16 cents. In the year so far, shares of ADMA have gained 5.2%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 63.57%.
In the past 30 days, the Zacks Consensus Estimate for Agenus’ 2023 loss per share has remained constant at 63 cents. During the same time frame, the consensus estimate for Agenus’ 2024 loss per share has remained constant at 45 cents. In the year so far, shares of AGEN have plunged 68.6%.
AGEN beat estimates in one of the trailing four quarters, matching in one and missing the mark on the other two occasions, delivering an average earnings surprise of 0.49%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate
GSK plc (GSK - Free Report) announced that it is in-licensing exclusive worldwide rights from China biopharmaceutical company, Hansoh Pharma, to develop and commercialize the latter’s investigational antibody-drug conjugate (ADC) candidate, HS-20093, in lung cancer and other solid tumor indications. However, Hansoh retains exclusive rights to the candidate in China’s mainland, Hong Kong, Macau, and Taiwan.
HS-20093 is a B7-H3 targeted ADC utilizing a clinically validated topoisomerase inhibitor payload. It is the second investigational ADC that GSK in-licensed from Hansoh.
It is important to note that in October 2023, GSK bought the first ADC from Hansoh, HS-20089. HS-20089 is a B7-H4 targeted ADC, currently being developed in China in mid-stage studies. Per GSK, HS-20089 has the potential to become a best-in-class treatment for ovarian and endometrial cancer with opportunities in other solid tumors.
Per the press release, HS-20093 is currently being evaluated in ongoing phase I and II studies in China. Data from the phase I ARTEMIS-001 study for HS-20093 in advanced solid tumors was recently presented at a medical conference. In the early-stage study, treatment with the candidate demonstrated initial clinical activity in small-cell lung cancer, non-small-cell lung cancer and sarcoma with multiple confirmed responses.
HS-20093 demonstrated a manageable safety profile, too, which was also encouraging.
Year to date, shares of GSK have gained 3% against the industry’s 16.9% decline.
Image Source: Zacks Investment Research
Per the terms of the agreement, GSK is liable to make an upfront payment of $185 million to Hansoh in consideration of the exclusive license to develop and commercialize HS-20093 for lung cancer and other solid tumor indications.
GSK might be further liable to pay potential milestone payments of up to $1.525 billion to Hansoh, which brings the total deal value to approximately $1.9 billion.
Additionally, GSK will make tiered royalty payments on global net sales of HS-20093 in its territories, subject to successful commercialization. The closing of the transaction is contingent upon the meeting of certain customary and regulatory conditions.
GSK has a strong portfolio of marketed drugs for oncology indications, primarily boosted by growth in Jemperli (dostarlimab) and Zejula (niraparib) sales, approved for various gynecologic cancer indications. In the first nine months of 2023, GSK’s oncology drugs together recorded revenues of £487 million, representing year-over-year growth of 9% at constant exchange rate.
GSK PLC Sponsored ADR Price and Consensus
GSK PLC Sponsored ADR price-consensus-chart | GSK PLC Sponsored ADR Quote
Zacks Rank and Stocks to Consider
GSK currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth mentioning are Puma Biotechnology, Inc. (PBYI - Free Report) , ADMA Biologics (ADMA - Free Report) and Agenus (AGEN - Free Report) . While PBYI sports a Zacks Rank #1 (Strong Buy), ADMA and AGEN carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for Puma Biotech’s 2023 earnings per share (EPS) has decreased from 73 cents to 72 cents. During the same time frame, the consensus estimate for Puma Biotech’s 2024 EPS has increased from 62 cents to 64 cents. In the year so far, shares of PBYI have lost 7.6%.
PBYI’s earnings beat estimates in three of the last four quarters while missing on one occasion, delivering a four-quarter average earnings surprise of 76.55%.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2023 loss per share has remained constant at 3 cents. The consensus estimate for ADMA Biologics’ 2024 EPS is pegged at 16 cents. In the year so far, shares of ADMA have gained 5.2%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 63.57%.
In the past 30 days, the Zacks Consensus Estimate for Agenus’ 2023 loss per share has remained constant at 63 cents. During the same time frame, the consensus estimate for Agenus’ 2024 loss per share has remained constant at 45 cents. In the year so far, shares of AGEN have plunged 68.6%.
AGEN beat estimates in one of the trailing four quarters, matching in one and missing the mark on the other two occasions, delivering an average earnings surprise of 0.49%.